Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
NCT03367871
Terminated
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: University of Miami, Miami, Florida
Conditions: Cervical Cancer
Register for Updates
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
NCT03719326
Completed
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with advanced metastatic triple-negative breast cancer (TNBC) or ovarian cancer, and etrumadenant in combination with nanoparticle albumin-bound-paclitaxel (NP) in participants with advanced metasta... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Scottsdale Healthcare Hospitals dba Honor Health Research Institute, Scottsdale, Arizona +26 locations
Conditions: TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Register for Updates
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03387098
Terminated
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Pancreatic Cancer
Register for Updates
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
NCT06338657
Recruiting
This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Los Angeles General Medical Center, Los Angeles, California +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
RegoNivo vs Standard of Care Chemotherapy in AGOC
NCT04879368
Active Not Recruiting
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +93 locations
Conditions: Gastro-Oesophageal Cancer
Register for Updates
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
NCT04672005
Active Not Recruiting
The main objective of the clinical trial is to determine if modified FOLFIRINOX (mFFX) alternated with biweekly Gemcitabine plus Nab-Paclitaxel (mGnabP) administered as a combined, front-line therapy will result in longer time to treatment failure (TTF) compared to the current standard of care with mFFX alone in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey +6 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03136406
Terminated
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Pancreatic Cancer
Register for Updates
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
NCT05921149
Not Yet Recruiting
Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed. Short term fasting protects against toxic effects of chemotherapy without decreasing efficacy. In a prospective clinical trial of breast cancer patients randomized to FMD or regular diet during chemotherapy, less antiemetic was required in the FMD group; radiographic and pathologic responses were better in this group. This trial tests whether platinum-taxane chemo... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2024
Locations: NorthShore University HealthSystem, Evanston, Illinois
Conditions: Ovarian Cancer, Chemotherapeutic Toxicity
Register for Updates
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
NCT04742959
Completed
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: City of Hope, Duarte, California +5 locations
Conditions: Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
Register for Updates
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
NCT01279291
Terminated
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Arizona Cancer Center, Tucson, Arizona +6 locations
Conditions: Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
Register for Updates
Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty
NCT02758847
Completed
The use of drug coated balloon (DCB) in patients with critical limb ischemia (CLI) and tissue loss has recently raised some concerns after the IN.PACT deep trial using paclitaxel coated balloon angioplasty in the tibial arteries was terminated. The investigators objective is to establish the safety and efficacy of drug coated balloon (DCB) for femoropopliteal occlusive disease in patients with critical limb ischemia (CLI) and tissue loss. The investigators objective is to establish the safety a... Read More
Gender:
ALL
Ages:
Between 40 years and 95 years
Trial Updated:
04/23/2024
Locations: Judith Brimmeier, Pittsburgh, Pennsylvania
Conditions: Ischemia
Register for Updates
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
NCT00070564
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Regional Medical Center, Anniston, Alabama +541 locations
Conditions: Breast Cancer
Register for Updates